Spark Therapeutics Reports 2017 Financial Results and Recent Business Progress
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
Spark Therapeutics (ONCE) PT Lowered to $64 at Stifel
February 20, 2018 6:00 PM ESTStifel lowered its price target on Spark Therapeutics (NASDAQ: ONCE) to $64.00 (from $73.00) while maintaining a Buy rating.
... MoreSpark Therapeutics (ONCE) PT Lowered to $100 at Cantor Fitzgerald; Reit. 'Overweight' Rating
February 20, 2018 1:33 PM ESTCantor Fitzgerald lowered its price target on Spark Therapeutics (NASDAQ: ONCE) to $100.00 (from $105.00) while maintaining an Overweight rating following Q4 results.
Analyst Elemer Piros commented, "We anticipate 2018 could become a transformative year for Spark with advancement of its hemophilia B program into Phase 3... More
